Back to Atlases main

BRCA1/2 Cancer Atlas

The mutations that cause cancer often arise spontaneously in somatic tissues but some are heritable. Among these mutations in BRCA1 or BRCA2 (BReast CAncer gene 1&2) stand out as having relatively high prevalence and causing a substantial increase in a variety of cancers including those of the breast, ovaries, pancreas and prostate. BRCA1 and BRCA2 are involved in the repair of damaged DNA but the precise events that initiate tumor formation are not fully understood.

Principal Investigators

  • Joan Brugge, PhD, Director of the Harvard Ludwig Cancer Center and Professor of Cell Biology, Harvard Medical School
  • Sandro Santagata, MD PhD, Associate Professor of Pathology, Brigham and Women’s Hospital and Harvard Medical School
  • Peter Sorger, PhD, Professor of Systems Biology, Harvard Medical School

Publications

A human breast atlas integrating single-cell proteomics and transcriptomics.

A human breast atlas integrating single-cell proteomics and transcriptomics.

Gray, G.K., Li, C.M.-C., Rosenbluth, J.M., Selfors, L.M., Girnius, N., Lin, J.-R., Schackmann, R.C.J., Goh, W.L., Moore, K., Shapiro, H.K., Mei, S., D’Andrea, K., Nathanson, K.L., Sorger, P.K., Santagata, S., Regev, A., Garber, J.E., Dillon, D.A., Brugge, J.S. (2022).
Developmental Cell, 57(22), 1400-1420. https://doi.org/10.1016/j.devcel.2022.05.003
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.

Mehta, A.K., Cheney, E.M., Hartl, C.A., Pantelidou, C., Oliwa, M., Castrillon, J.A., Lin, Lin, J.-R., ... Guerriero, J. (2021).
Nature Cancer, 2(1), 66–82. https://doi.org/10.1038/s43018-020-00148-7
Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer.

Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer.

Keenan, T.E., Li, T., Vallius, T., Guerriero, J.L., Tayob, N., Kochupurakkal, B., Davis, J., Pastorello, R., ... Tolaney, S.M. (2021).
Clinical Cancer Research, 2(1), 66-82. https://doi.org/10.1158/1078-0432.CCR-20-3089

Data Explorations

Data Explorations are like museum guides and exploit the digital docents in MINERVA to guide readers through the complexities of a large image dataset via a series of narrated stories and waypoints.

Data image
BRCA WT vs BRCA1 associated TNBC

Data Overviews

Data Overviews provide access to minimally processed Level 2 images with no annotation or quality control. Click any of the following thumbnail images for an interactive view of the full-resolution images.

Data image
Ovarian Cancer with Annotation - LSP15343
Data image
Ovarian Cancer with Annotation - LSP15327
Data image
MITI - LSP15343
Data image
LSP16696
Data image
LSP16697
Data image
LSP16698
Data image
LSP16699
Data image
LSP16814
Data image
CK1 (BRCA wildtype)
Data image
CK2 (BRCA wildtype)
Data image
CK3_R (BRCA wildtype)
Data image
CK4_P (BRCA wildtype)
Data image
CK4_R (BRCA wildtype)
Data image
CK5 (BRCA wildtype)
Data image
CK6 (BRCA wildtype)
Data image
CK7 (BRCA wildtype)
Data image
CK8 (BRCA wildtype)
Data image
CK9 (BRCA wildtype)
Data image
CK10 (BRCA wildtype)
Data image
CK11 (BRCA wildtype)
Data image
CK12 (BRCA wildtype)
Data image
CK13 (BRCA wildtype)
Data image
CK14 (BRCA wildtype)
Data image
CK15 (BRCA wildtype)
Data image
CK16 (BRCA wildtype)
Data image
CK17_M (BRCA wildtype)
Data image
CK18_P (BRCA wildtype)
Data image
CK19_BCC (BRCA wildtype)
Data image
CK19_BCC2 (BRCA wildtype)
Data image
CK20 (BRCA wildtype)
Data image
CK21 (BRCA wildtype)
Data image
CK22 (BRCA wildtype)
Data image
CK23 (BRCA wildtype)
Data image
CK24 (BRCA wildtype)
Data image
CK25_R (BRCA wildtype)
Data image
CK26 (BRCA wildtype)
Data image
W2BC_3 (BRCA wildtype)
Data image
W8B_4 (BRCA wildtype)
Data image
K1 (BRCA mutant)
Data image
K2 (BRCA mutant)
Data image
K3 (BRCA mutant)
Data image
K4 (BRCA mutant)
Data image
K5 (BRCA mutant)
Data image
K6 (BRCA mutant)
Data image
K7 (BRCA mutant)
Data image
K8 (BRCA mutant)
Data image
K9 (BRCA mutant)
Data image
K10 (BRCA mutant)
Data image
K11 (BRCA mutant)
Data image
K12 (BRCA mutant)
Data image
K13 (BRCA mutant)
Data image
K14 (BRCA mutant)
Data image
K15 (BRCA mutant)
Data image
K16 (BRCA mutant)
Data image
K17 (BRCA mutant)
Data image
K18 (BRCA mutant)
Data image
K19 (BRCA mutant)
Data image
K20 (BRCA mutant)
Data image
K21 (BRCA mutant)
Data image
K22 (BRCA mutant)
Data image
K23 (BRCA mutant)
Data image
K24 (BRCA mutant)
Data image
K26 (BRCA mutant)
Data image
K27 (BRCA mutant)
Data image
jenntnbc4m33118
Data image
BRCA1-associated-9
Data image
BRCA1-associated-8
Data image
BRCA1-associated-7
Data image
BRCA1-associated-6
Data image
BRCA1-associated-5
Data image
BRCA1-associated-4
Data image
BRCA1-associated-3
Data image
BRCA1-associated-2
Data image
BRCA1-associated-10
Data image
BRCA1-associated-1
Data image
BRCA WT vs BRCA1 associated TNBC
Data image
BRCA-WT-6
Data image
BRCA-WT-5
Data image
BRCA-WT-4
Data image
BRCA-WT-3
Data image
BRCA-WT-2
Data image
BRCA-WT-1
Data image
Clinical Benefit - Cisplatin Biopsy
Data image
Clinical Benefit - Cis Wee1i Biopsy
Data image
No Clinical Benefit - Cis Wee1i Biopsy
Data image
No Clinical Benefit - Cisplatin Biopsy

Funding

This research is funded by the Gray Foundation Basser Initiative, the Ludwig Institute for Cancer Research, and the National Cancer Institute (NCI U54 CA225088).